查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
细胞裂解市场增长、趋势、COVID-19 的影响和预测 (2023-2028)
市场调查报告书
商品编码
1190257

细胞裂解市场增长、趋势、COVID-19 的影响和预测 (2023-2028)

Cell Lysis Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，细胞裂解市场预计将以 8.5% 的复合年增长率增长。

COVID-19 大流行对呼吸系统的严重影响促使人们迫切需要新疗法并增加药物发现的数量，从而对细胞溶解市场产生积极影响。 已经进行了几项研究以了解细胞溶解对冠状病毒的影响。 例如，在 COVID-19 大流行高峰期，印度生物技术部 (DBT) 开展了一个项目，对样本中的 1,000 个 SARS-CoV-2 基因组进行测序，以了解病毒在稻田中的进化行为。 在印度各地收集了样本，以研究病毒的新突变以及它们如何改变疾病的症状。 使用各种过程的研究活动的增加增加了对细胞裂解设备和试剂的需求。

由于研发支出的增加、製药和生物製药行业应用的扩大以及对个性化医疗的日益关注，预计该市场将会增长。 个体化医疗是遗传学相关研究的最新趋势之一，根据患者的具体需求提供量身定制的治疗方案，对疾病的预防、诊断、预后和治疗具有重要意义。我有。 根据 GLOBOCAN 的数据，2020 年全球将新增约 19,292,789 名癌症患者，约有 9,958,133 人死于癌症。 随着传染病和癌症的增加，用于研发的细胞样本也在增加，这有望支持细胞裂解市场的增长。

在製造生物治疗药物和其他重组产品的下游过程中，细胞裂解和破碎方法的高采用率也推动了整个市场的增长。 此外，政府和私人组织增加对与生物技术过程和学术界相关的研发的投资预计将显着推动市场。 然而，微尺度应用中的法规遵从性和机械过程问题是可能阻碍市场增长的一些因素。

细胞裂解市场的趋势

预计未来几年仪器将出现显着增长

仪器是用于裂解细胞的工具或设备。 它们进一步分为超声发生器、均质器、法压机、微流化器等。 均质器和超声仪等仪器主要用于细胞裂解/细胞分离，随着超声仪越来越多地用于细胞分离，需求量最大。

细胞裂解的最新进展使得在细胞裂解过程中出现了微流体装置。 例如，根据《生物技术杂誌》2022 年 4 月发表的一项研究，微流体技术广泛用于细胞裂解。 红细胞的分离和裂解可用于诊断多种疾病，从而增加了对细胞裂解中微流体装置的需求，并促进了市场增长。

随着慢性病和传染病数量的增加，研究实验室和研究机构以及生物製药和生物技术公司的需求增加，推动了整体医药需求。 例如，根据美国癌症协会2022年发布的报告数据，预计2022年美国将新增约1,918,030例癌症病例。 如此多的癌症患者表明需要研究和诊断这种□□疾病，这有望推动这一领域的增长。 用于细胞破碎和裂解的工具的商业可用性和可靠性也在推动这一领域的增长。

北美有望在预测期内主导市场

由于研发支出增加和慢性病发病率增加，北美在细胞溶解市场处于领先地位。 随着 COVID-19 的兴起，实验室测试技术的增加有望加强细胞裂解市场的发展。 此外，研究 COVID-19 细胞反应和开发疫苗的科学家对细胞裂解系统和试剂产生了巨大需求。 因此，该地区越来越多的研究对市场产生了积极影响。

对用于治疗癌症的细胞疗法的需求不断增加，预计也将促进细胞溶解市场的增长。 北美几种疾病的患病率和发病率上升以及研发支出的增加正在推动所有生命科学学科对先进研发方案的需求。 根据药物研究与製造商协会 (PhRMA) 的数据，到 2021 年，美国公司将进行全球一半以上的药物研发。 同一份文件称，2021 年美国在生物製药研发方面的投资约为 1020 亿美元。

因此，美国医疗保健基础设施的持续增长和患者人数的增加为临床实验室的扩张提供了广阔的机会，并将促进市场增长。

细胞裂解市场竞争分析

这个市场由国内外公司组成，竞争很低。 一些参与者包括 Thermo Fisher Scientific Inc.、Merck KGaA、F. Hoffmann-La Roche Ltd、Qiagen NV、Becton 和 Dickinson and Company。 这些公司正专注于新产品开发、收购和合作，以提高其市场地位。 随着製药和生物技术领域的进步，不少中小企业进入了这个市场。 相信在未来，这些公司将占据研究市场的重要份额。 此外，由于新产品的推出，该市场的竞争正在加剧。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 研发费用增加
    • 在製药和生物製药行业的应用增加
    • 对个性化医疗越来越感兴趣
  • 市场製约因素
    • 对法规的回应
    • 微尺度应用的机械过程问题
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（市场规模：百万美元）

  • 按产品类型
    • 设备
      • 均质机
      • 离心机
      • 其他产品类型
    • 试剂
  • 按细胞类型
    • 哺乳动物细胞
    • 微生物细胞
    • 植物细胞
  • 最终用户
    • 生物技术公司、生物製药公司
    • 研究机构和学术机构
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • Danaher Corporation
    • Eppendorf AG
    • F. Hoffmann-La Roche Ltd
    • Labfreez Instruments Group Co. Ltd
    • Merck KGaA
    • Qsonica LLC
    • Takara Bio Inc.
    • Thermo Fisher Scientific Inc.
    • Cell Signaling Technology Inc.
    • Miltenyi Biotec
    • QIAGEN NV
    • Claremont BioSolutions LLC
    • Microfluidics International Corporation

第7章 市场机会与今后动向

简介目录
Product Code: 62783

The cell lysis market is expected to register a CAGR of 8.5% over the forecast period.

Severe respiratory consequences of the COVID-19 pandemic prompted an urgent need for novel therapies that increased the number of drug discoveries, thereby positively impacting the cell lysis market. Several research studies were conducted to understand the effect of cell lysis on coronavirus. For instance, during the peak of the COVID-19 pandemic, the Department of Biotechnology (DBT) in India undertook a project to sequence 1,000 SARS-CoV-2 genomes from samples to understand the evolving behavior of the virus. The samples were collected across India to study the emerging mutations in the virus and how they change the symptoms of the disease. The increase in research activities that used different processes increased the demand for cell lysis devices and reagents.

​The market is expected to grow due to increased expenditure on research and development, increasing application in the pharmaceutical and biopharmaceutical industries, and a rising focus on personalized medicine. Personalized medicine is one of the latest developments of gene-related studies that provide custom-tailored treatments as per the specific needs of patients, which has massive significance in disease prevention, diagnosis, prognosis, and therapeutics. According to the GLOBOCAN, in 2020, there were around 19,292,789 new cancer cases worldwide and about 9,958,133 deaths due to cancer. With the increase in the prevalence of infectious diseases and cancers, the use of cell samples for research and development of drugs also increases, which is expected to support the growth of the cell lysis market.

The high adoption of cell lysis and disruption methods during downstream processing to manufacture bio-therapeutics and other recombinant products further boosts the overall market growth. Furthermore, rising investments by governments and private organizations in R&D related to biotechnological processes and academics are expected to drive the market significantly. However, regulatory compliance and issues in the mechanical process in applying at the microscale level are some factors that might hinder market growth.

Cell Lysis Market Trends

Instruments are Expected to Witness Significant Growth in the Coming Years

Instruments are tools or devices used to lyse the cells. They are further categorized as sonicators, homogenizers, French press, microfluidizers, and others. Instruments like homogenizers and sonicators are used mostly for cell lysis/cell fractionation, and sonicators have the highest demand due to their increasing use in cell fractionation.

Recent advancements in cell lysis allowed the emergence of microfluidic devices in the cell lysis process. For instance, as per a study published by a Biotechnology Journal in April 2022, microfluidic technology is widely used for cell lysis. Separation and lysis of RBCs are helpful in the diagnosis of several diseases, which augments the demand for microfluidics in cell lysis, thus contributing to market growth.

With the rising number of chronic diseases and infectious diseases, there is a high demand in research laboratories and institutes and biopharmaceutical and biotechnology companies, which boosted the overall drug demand. For instance, as per the data from the American Cancer Society report published in 2022, around 1,918,030 new cancer cases were expected in United States in 2022. This high number of cancer cases indicates the need for research and diagnosis of the disease, which is expected to propel the growth of the segment . The commercial availability and reliability of tools used in cell disruption and lysis also boost the growth of this segment.

North America is Expected to Dominate the Market Over the Forecast Period

North America is spearheading the cell lysis market due to the increasing expenditure on research and development and increasing incidence of chronic diseases. With the rise in COVID-19, there was an increase in lab testing techniques, which was anticipated to intensify the progress of the cell lysis market. Furthermore, scientists researching COVID-19 cellular response and developing vaccines created a huge demand for cell lysis systems and reagents. Thus, increasing research in the region had a positive impact on the market.

The increasing demand for cell-based therapies for the treatment of cancer is also expected to augment the growth of the cell lysis market. The increasing prevalence and incidence of several diseases and rising research and development expenditure in North America trigger the need for an advanced research and development scenario across all life sciences sectors. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), in 2021, US companies conducted over half the world's research and development in pharmaceuticals. The same source stated that approximately USD 102 billion was invested in biopharmaceutical R&D in United States in 2021. ​

Hence, the continuous growth of healthcare infrastructure in United States and the increase in the patient population provide wider opportunities for clinical laboratories to expand and help boost market growth.

Cell Lysis Market Competitive Analysis

The market studied is moderately competitive and consists of local and international companies. Some players include Thermo Fisher Scientific Inc., Merck KGaA, F. Hoffmann-La Roche Ltd, Qiagen NV, Becton, and Dickinson and Company, among others. These companies focus on novel product developments and acquisitions/collaborations to enhance their market positions. With advancements in the pharmaceutical and biotechnology sector, few small to mid-sized companies have entered the market. It is believed that these companies will hold a substantial share of the market studied in the future. Competition is also increasing due to new product launches in this market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Expenditure in Research and Development
    • 4.2.2 Increasing Application in the Pharmaceutical and Biopharmaceutical Industries
    • 4.2.3 Rising Focus on Personalized Medicine
  • 4.3 Market Restraints
    • 4.3.1 Regulatory Compliance
    • 4.3.2 Issues in Mechanical Process to Apply at the Microscale Level
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size - Value in USD million)

  • 5.1 By Type of Product
    • 5.1.1 Instruments
      • 5.1.1.1 Homogeniser
      • 5.1.1.2 Centrifugation
      • 5.1.1.3 Other Types of Products
    • 5.1.2 Reagents
  • 5.2 By Type of Cells
    • 5.2.1 Mammalian Cells
    • 5.2.2 Microbial Cells
    • 5.2.3 Plant Cells
  • 5.3 By End User
    • 5.3.1 Biotechnology or Biopharmaceutical Companies
    • 5.3.2 Research Laboratories and Academic Institutes
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 COMPANY PROFILES
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 Bio-Rad Laboratories Inc.
    • 6.1.3 Danaher Corporation
    • 6.1.4 Eppendorf AG
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Labfreez Instruments Group Co. Ltd
    • 6.1.7 Merck KGaA
    • 6.1.8 Qsonica LLC
    • 6.1.9 Takara Bio Inc.
    • 6.1.10 Thermo Fisher Scientific Inc.
    • 6.1.11 Cell Signaling Technology Inc.
    • 6.1.12 Miltenyi Biotec
    • 6.1.13 QIAGEN NV
    • 6.1.14 Claremont BioSolutions LLC
    • 6.1.15 Microfluidics International Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS